23:41 , Jan 25, 2019 |  BioCentury  |  Finance

Kurma’s Munich move

Kurma Partners has opened a Munich office to spin out German academic science into biotechs in a bid to apply its company creation model to bridge the country’s venture capital gap for translating compelling research....
22:12 , Dec 14, 2018 |  BioCentury  |  Finance

Spreading good Kurma

Declaring its last fund’s preseed partnership approach a success, Kurma Partners S.A. is expanding its model to build more new companies across Europe through its new Biofund III. For its 2016 Biofund II, the VC...
15:40 , Dec 14, 2018 |  BC Extra  |  Financial News

Kurma announces first close of €150 million Biofund III

Kurma Partners S.A. completed the first close of its third fund, Kurma Biofund III, which is targeting a final close of €150 million ($169.4 million) in 2019. The firm declined to disclose the size of...
21:40 , Sep 25, 2018 |  BC Extra  |  Company News

Management tracks: Curis, Gemphire

Cancer company Curis Inc. (NASDAQ:CRIS) named COO James Dentzer president and CEO and appointed him as a board member. He replaces Ali Fattaey, who is departing. Curis had promoted Dentzer to COO this year. Cardiometabolic...
20:15 , May 25, 2017 |  BC Innovations  |  Finance

Europe’s translational springtime

European science is showing early signs of translational growth, with VCs increasingly shifting their focus to preclinical assets. But investors are concerned the region still doesn’t have the supply of management talent or funding it...
21:03 , Jan 19, 2017 |  BC Innovations  |  Finance

Kurma chameleon

French life science VC Kurma Partners S.A. is experimenting with a new investment model to accelerate the transfer of European academic research into the commercial setting with less risk than standard seed investments. The firm...
07:00 , Oct 24, 2016 |  BC Week In Review  |  Financial News

Ysios Capital financial update

Ysios Capital, Barcelona, Spain  Business: Finance  Date announced: 2016-10-18  Note: Ysios Capital closed its Ysios BioFund II Innvierte fund at EUR126.4 million ($138.7 million), exceeding its initial target of EUR100 million ($109.8 million). The firm...
07:00 , Oct 24, 2016 |  BioCentury  |  Finance

Eyes on Spain

Ysios Capital Partners kept the doors open for its second fund longer than expected to welcome a new crop of deep-pocketed LPs who took interest in the firm’s latest investments. Ysios BioFund II Innvierte launched...
07:00 , Oct 18, 2016 |  BC Extra  |  Financial News

Ysios closes EUR 126.4M fund

Spanish venture firm Ysios Capital Partners closed its second fund, Ysios BioFund II Innvierte, with EUR 126.4 million ($138.7 million). The raise was above its EUR 100 million ($109.8 million) target (see BioCentury Extra, March...
07:00 , May 19, 2016 |  BC Innovations  |  Finance

Found in translation

Mark Zipkin, Staff Writer  With almost $1 billion in new venture funds in the last year and a half aimed at academic research, Europe is showing signs of a dedicated effort among investors and universities...